S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

LON:STXShield Therapeutics Share Price, Forecast & News

GBX 117
+8.00 (+7.34 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
109.12
Now: GBX 117
118.67
50-Day Range
82
MA: GBX 94.92
127
52-Week Range
0.88
Now: GBX 117
195
Volume94,691 shs
Average Volume48,665 shs
Market Capitalization£137.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Read More
Shield Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5118500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£719,000.00
Cash FlowGBX 4.43 per share
Book ValueGBX 27.40 per share

Profitability

Miscellaneous

Employees15
Market Cap£137.11 million
Next Earnings DateN/A
OptionableOptionable
GBX 117
+8.00 (+7.34 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Shield Therapeutics (LON:STX) Frequently Asked Questions

How has Shield Therapeutics' stock price been impacted by Coronavirus?

Shield Therapeutics' stock was trading at GBX 121.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, STX shares have decreased by 3.7% and is now trading at GBX 117.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Shield Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Shield Therapeutics
.

What price target have analysts set for STX?

2 brokerages have issued 1-year price objectives for Shield Therapeutics' shares. Their forecasts range from GBX 200 to GBX 200. On average, they expect Shield Therapeutics' share price to reach GBX 200 in the next year. This suggests a possible upside of 70.9% from the stock's current price.
View analysts' price targets for Shield Therapeutics
.

Has Shield Therapeutics been receiving favorable news coverage?

News coverage about STX stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Shield Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Shield Therapeutics
.

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX).

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the following people:
  • Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
  • Mr. Timothy William Watts, Chief Financial Officer (Age 61)
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 117.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £137.11 million and generates £719,000.00 in revenue each year. Shield Therapeutics employs 15 workers across the globe.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is www.shieldtherapeutics.com.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.